Topic Archives: Forbes

Comments

  • Travis Johnson, Stock Gumshoe

    Hi Gordie, welcome to our space and thanks for commenting... yes, the promoters often try to add gravitas by including m...

  • Avatar

    Is there an update on the Nasdaq cryptocurrency? The latest thing I've been able to dig up on this was an article by a F...

  • mjorrin

    I've never heard of that particular one, but "a cure for every cancer" is exceedingly unlikely. A tiny bit of digging ...

  • Avatar

    Even back in July 2018, Forbes had an article quoting Terry Gou (head of Foxconn) stating that his goal for stock price ...

  • Avatar

    They know more that the business inside and out the ceo was the original ceo of canopy the list of as they refer to it a...

  • Avatar

    I agree with your first comment completely. Forbes I'm not familiar with judging that they are a financial mag and the l...

  • Avatar

    In fact, an article in Forbes magazine states "In reality, the EWG, which has been dubbed the Environmental Worry Group,...

  • Avatar

    Hi isight, Forbes included an article citing some concerns about Telegram in Feb. As a tangent, through professional ch...

  • Gr8Full!

    Lots of good info from EndPoints: NEW Judgment day is coming: Federal judge orders Martin Shkreli to forfeit a small ...

  • Avatar

    So far all I can find is that after raising $850 billion they decided to have a second private ico round. While they wer...

  • Avatar

    $CWBR#MindBlowing#Thank you Dr. KSS: Excellent Article: Forbes Magazine: "The Cult of DNA-centricity" https://www.for...

  • Gr8Full!

    $NVS, GWPH... $SGYP Needs to raise $25-30m in cash by Jan 31st. Debt covenant shows they need $128m of cash Jan 31s...

  • Avatar

    $ESPR re: today's 10%+ share price decline (ouch) three possible culprits . 1) sharp pullback from a fairly torrid rise...

  • SoGiAm

    $ONCE, $PFE... NEW http://e.endpointsnews.com/t/ViewEmail/t/09E2A4F6D4C4E999/2F80028A944F69C925D77A725F39070E Park...

  • Avatar

    No experience with customer service, hence voted only on the other items. Best for analysis & quality of writing., w...

  • Avatar

    Travis Good afternoon. Have you looked at Wealthy Retirement touting "Impossible Matter" Found on Jupiter Could Cut Elec...

  • Avatar

    Hello. You seem to have time and desire to research things, and report them here. Would you be so kind as to research ...

  • Avatar

    1 Stock to Buy for the Return of "iPhone Mania" iPhone madness is back. And one little known company is allowing Apple t...

  • Avatar

    $NVS - Was surprised I was the first to post about this, but double-checked and saw the above link from rfyjr. I add...

  • Avatar

    $AUPH HI Denny, just a quick answer to your question. Please be reminded that the ParabolicSAR matrix is a "moving ta...

  • Avatar

    $AUPH's major shareholder: Robert Duggan Featured in Forbes: https://www.forbes.com/profile/robert-duggan/ Best, H...

  • Avatar

    That's an interesting form of prevarication, especially in light of something I read just the other day by a former Forb...

  • Avatar

    you have to watch those money back guarantees. Forbes got me to sign up for one of their investment newsletters. The pre...

  • Avatar

    ABEO with some good ink in Forbes article. This may be one I have to squeeze in portfolio down the road. https://www.fo...

  • Avatar

    Sharon, I have created a .pdf file of the Forbes article, if someone can tell be how to do it, I will upload it or send ...

  • Avatar

    $no ticker. Danmcco, I don't know if its the Forbes website, but I tried various methods to get to the site without su...

  • Avatar

    In my opinion, Weiss has missed many investment returns because they seem to favor Conservative Republicans when histor...

  • Avatar

    $AKAO $AKBA An interesting article from Forbes, just in: "Four stocks moving both on the news and the charts" ...

  • Avatar

    $BIOC - This may be a new Forbes article, but the news goes back to last year and has been commented on here in the past...

  • Avatar

    Do you ever wonder how all those politicians arrive in Washington with "regular" wealth, earn $174,000 a year for a few ...

  • Avatar

    $SCYX (long) Great article, Doc - and very timely. The controversial clinical hold action in this case exemplifies t...

  • Avatar

    https://www.axios.com/business-media-has-its-own-fake-news-problem-2353912512.html Many already know this, but for th...

  • Avatar

    Interesting Article in Forbes tonight about Amgen and ESPR mentioned. Here the link https://www.forbes.com/sites/davidg...

  • Avatar

    $ESPR: Basically, all the arguments in the articles I read today (NEJM, Forbes, IBD et all.) were alluded to in my fir...

  • Avatar

    $ESPR New Forbes article on this subject, just in: "Amgen drug prevents heart attacks, not deaths, disappointing e...

  • Anamorph

    Thank YOU for the kind comments, Tony. While Twitter is very speedy, you are correct that the noise-to-signal (sic) r...

  • SoGiAm

    A Complete Beginner's Guide To #Blockchain via @forbes http://www.forbes.com/sites/bernardmarr/2017/01/24/a-complete-b...

  • Avatar

    Hi Cleveland, Can you research $CYDY finances, will they have to raise equity before completion of HIV Tx. Pro140 Phase...

  • Avatar

    Related to this, an interesting proposal out of Forbes today advocating for the U.S government to buy Gilead to the tune...

  • Avatar

    Seems our little AUPH made the Forbes Dean's list for 2017 as a big idea. Great ink for them because Forbes reach's a lo...

  • Avatar

    Once again thanks for your candor and thoroughness. The Forbes Billionaire Portfolio ad was enticing, but aren't they al...

  • Avatar

    Does anyone have experience with Forbes Billionaire Portfolio newsletter. Sounds intriguing but don't they all!...

  • Avatar

    I've been tuning in to updates from the Forbes 2016 Healthcare Summit in the hope many of the big players attending woul...

  • Avatar

    Came across this in Forbes on gold. What's a person to do? Check out this link on gold http://www.forbes.com/sites/johnw...

  • Avatar

    Here is a Forbes article to illustrate my point: http://www.forbes.com/sites/wallaceforbes/2015/04/28/6-smid-caps-wit...

  • SoGiAm

    Forbes: Innovative Companies: http://www.forbes.com/innovative-companies/#79707158f172...

  • Avatar

    $ESPR, $AMGN, $SNY, $PFE New Atherosclerosis Study Results Bode Well For PCSK-9 Cholesterol-Lowering Drugs John LaMa...

  • Avatar

    PTLA, KITE, BLUE, INCY mentioned in this Forbes article as possible take over candidates. http://www.forbes.com/sites...

  • Avatar

    Travis Off topic. I don't know how to submit this for your perusal, so am posting it here in case you want to do a tea...

  • Avatar

    Travis, I am one of Jim Rickards' subscribers so I can tell you that his "World Money" play is actually something you w...

  • Avatar

    Forbes was writing about "Deep Learning And Machine Intelligence " in an article dating to 2014. http://www.forbes.com/s...

  • SoGiAm

    Here is discussion which includes a Forbes article and links describing ETC, ETH, the hard fork and Kraken. http://ww...

  • Avatar

    http://www.forbes.com/sites/anthonykosner/2014/12/29/tech-2015-deep-learning-and-machine-intelligence-will-eat-the-world...

  • Avatar

    $ESPR http://www.esperion.com/note-from-our-ceo/ This is Tim Mayleben – CEO of Esperion Therapeutics with some tho...

  • Avatar

    Juno: ''Remarkably, Juno gave the news about the hold to Forbes writers ahead of the announcement.'' That sounds like tr...

  • SoGiAm

    How Deep Learning Networks Can Use Virtual Worlds To Solve Real World Problems - Forbes http://buff.ly/1Nl23dW #ai htt...

  • SoGiAm

    How Deep Learning Networks Can Use Virtual Worlds To Solve Real World Problems - Forbes http://buff.ly/1Nl23dW #ai...

  • Avatar

    Will leave comment on this article to the experts here, but interestingly did just read this article from Forbes on fili...

  • Avatar

    Forbes article on how GILD can double in 3 years. http://www.forbes.com/sites/kenkam/2016/04/15/gild-future-biotech-fun...

  • Avatar

    From Forbes -- the largest biotech you never heard of... http://www.forbes.com/sites/matthewherper/2016/04/13/the-god-p...

  • Avatar

    Travis 2.1 billion Zuckerburg is NVDA tease based Zucks investment in Virtual Reality. Forbes just released their ann...

  • Avatar

    Forbes article with ESPR mentioned. http://www.forbes.com/sites/matthewherper/2016/04/03/some-people-really-cant-take...

  • Dr. KSS MD PhD

    No, he really did mean Unum Therapeutics. It's a private CAR-T variant play that has been financed by venture capitalist...

  • sogiam

    Forbes Names Cannabis CEO to Prominent List: http://mjbizdaily.com/forbes-names-cannabis-ceo-to-prominent-list/ Best2A...

  • Avatar

    In July 2015, Forbes reported on twitter, "It’s safe to say that cloud computing is the next “big thing.” http...

  • Avatar

    Back to the title article, from Forbes we get: Want to Fight a Deadly Fungus? San Diego's Amplyx Just Got $41M For That...

  • Avatar

    That Forbes list link led to only five stocks, and the timeline under each was for 2011. Heartland Payment Systems HPY ...

  • Avatar

    Investors have lost literally hundreds of thousands getting into such "ground-floor" companies. Without understanding wh...

  • Avatar

    GILD mentioned as blue chip bargain by Forbes. http://forbesmags.com/slp/blue_chip_oct15.pdf Cheers,Glenn...

  • sogiam

    The Future Of Medicine -- Where Investors Are Putting Their Money: http://www.forbes.com/sites/realspin/2015/05/01/the-...

  • Avatar

    Glenn: I came across that article too, it's pretty lame--he has a cursory at best knowledge of these companies, but it's...

  • Avatar

    Forgot to mention PTLA was mentioned in Forbes article as well. Cheers,Glenn...

  • Avatar

    ZFGN and ESPR mentioned in Forbes article. http://www.forbes.com/sites/greatspeculations/2015/10/09/biogen-and-four-oth...

  • Avatar

    $ESPR Forbes Pharma & Healthcare Amgen's Acquisition Of Dezima And CETP Drug Like Pfizer's '03 Buy Of Esperion. Will ...

  • Avatar

    Forbes Pharma & Healthcare - David Sable, Contributor Five Reasons Why Your Biotech Comparative Value Theory Is Wrong ...

  • Avatar

    From John LaMattina @ Forbes: Will Alnylam's New PCSK-9 Cholesterol Lowering Drug Be A Blockbuster? "before christen...

  • Avatar

    Interesting article in Forbes: When Doctors Invest: Dumb Mistakes And Offsetting Advantages By David Sable , Contrib...

  • Avatar

    The New Cholesterol Lowering Drugs Epitomize The Drug Pricing Battles John LaMattina , Contributor I cover news on d...

  • Avatar

    Interesting Forbes article on NDA's and approvals. http://www.forbes.com/sites/matthewherper/2015/08/25/nine-explanatio...

  • Avatar

    Forbes on PTN -- take your profit and run: http://www.forbes.com/sites/johnlamattina/2015/08/18/you-can-call-it-the-fem...

  • Avatar

    Forbes point of view on patient death in KITE trial. http://www.forbes.com/sites/matthewherper/2015/08/17/patient-death...

  • Avatar

    Just watched the Theranos TED talk yesterday--most interesting It is private company. They have already raised $400 m...

  • Avatar

    Read an article in my Forbes magazine, Issue July 20 regarding Docker. Assume that is the business you are referring ...

  • Avatar

    Forbes view on JUNO/CELGENE deal. http://www.forbes.com/sites/stephenbrozak/2015/06/30/did-celgenes-billion-dollar-deal...

  • Avatar

    ESPR This from Forbes (not that positive about Esperion) Why Esperion Shares Are Down 18% Today Shares of Esper...

  • Subramania

    I see this Forbes article from Matt saying $ESPR needs to worry since they may need large trials. http://www.forbes.c...

  • Anamorph

    Interesting and very public battle going on about this drug, and the issues are at least as much politics and perception...

  • Avatar

    There's only a fixed number of services that they remarket over and over with different copywriting. Occasionally they ...

  • Avatar

    Forbes Biotech report. http://www.forbes.com/sites/luketimmerman/2015/05/23/what-you-may-have-missed-in-biotech-eye-dru...

  • Avatar

    ESPR Chardan managed to get lame hit piece into Forbes: http://blogs.barrons.com/stockstowatchtoday/2015/05/22/esperio...

  • Avatar

    $LNEGY Siluria (wi) news article 10 days ago in Forbes sez Paul Allen of Vulcan Capital is now in Siluria and they i...

  • Avatar

    Great story written today at Forbes on Immune system combo drugs to fight cancer. http://www.forbes.com/sites/matthewhe...

  • Avatar

    If you haven't seen the currently running 3-part Cancer series on PBS, I recommend you catch it. Part 2 tonight and p3 t...

  • Avatar

    I find excellent information with Forbes as they discuss everything from current to future companies moving forward and ...

  • Dr. KSS, MD PhD

    No, it is real, and serious. What I hate are disgruntled pompous Trotskyite arses like Matthew Herper whining on Forbes ...

  • Vijay Panikar

    ( ACT, CELG , GILD, NOV) Matthew Herper , Forbes Staff reporter has ranked the large pharmacopoeias. .Top Of The C...

  • Avatar

    Jean_Pierre, Very interesting- I bought a few shares fairly early on the 19th around $38 and it's now around $40. How B...

  • Avatar

    Sharon, that would be a hard for me to choose between them but if I had to it would most likley be Kite.Both look to be...

  • Avatar

    David...Have you caught this Forbes follow-up on the good doctor? http://www.forbes.com/sites/matthewherper/2014/12/07/...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch